01. The paradox at the centre of PTH pharmacology

Parathyroid hormone (PTH) is an 84-amino-acid peptide secreted by the parathyroid glands and the principal regulator of serum calcium. Its effect on bone depends less on the hormone itself than on the pattern of exposure. Continuous excess of endogenous PTH — as occurs in primary hyperparathyroidism — stimulates bone resorption more than bone formation and is detrimental to the skeleton. Once-daily, transient ("pulsatile") exposure does the opposite: it preferentially stimulates osteoblastic bone formation, producing a net anabolic effect (EMA EPAR Forsteo). This exposure-dependence, sometimes called the anabolic window, is the reason PTH analogues are given as short daily pulses rather than steady infusions, and it is a textbook illustration of a principle Peptide Data applies throughout: exposure is not the same as effect.

02. Teriparatide — the recombinant fragment that defined the class

Teriparatide is the 34 N-terminal amino acids of human PTH — rhPTH(1-34) — produced by recombinant DNA technology. It binds the PTH type 1 receptor (PTH1R) with the same affinity as full-length PTH and shares its physiological actions on bone and kidney. Administered as a once-daily subcutaneous injection, it was first authorised in the European Union in 2004 for established osteoporosis in postmenopausal women, where it reduced vertebral (though not, at that point, hip) fracture incidence (EMA EPAR Forsteo). It is a prescription-only medicine in the UK.

NICE positions teriparatide, alongside romosozumab and oral bisphosphonates, as one of the anabolic options for osteoporosis after menopause, reserved for people at high or very high fracture risk (NICE TA991). Its use is time-limited: the European product information caps treatment at 24 months, a precaution shaped by a rodent osteosarcoma signal seen at high cumulative exposure, alongside the need to monitor for transient hypercalcaemia (EMA EPAR Forsteo).

03. Abaloparatide — receptor-state selectivity as a design feature

Abaloparatide is not a PTH fragment. It is a synthetic analogue of parathyroid hormone-related protein (PTHrP 1-34), a distinct endogenous peptide. Both it and teriparatide signal through PTH1R, but the receptor adopts two high-affinity states, termed R0 and RG: ligands that favour R0 drive more prolonged signalling, while RG-selective ligands produce a shorter, more transient response. Abaloparatide binds the RG state more selectively than teriparatide, and this more transient signalling is the rationale offered for a somewhat more favourable balance of bone formation over resorption (Cosman 2022).

NICE TA991 recommends abaloparatide as an option for osteoporosis after menopause in women, trans men and non-binary people at very high fracture risk, positioned as an alternative to romosozumab or teriparatide. Where all three are considered suitable, NICE advises using the least expensive option, taking administration costs and commercial arrangements into account. It found that indirect comparisons suggest abaloparatide is likely at least as effective as its comparators, while noting the absence of adequately powered head-to-head randomised data (NICE TA991).

Honesty about the evidence matters here. The ACTIVE randomised trial established a reduction in new vertebral fractures versus placebo (Miller 2016). A large US claims database study found non-vertebral and hip fracture rates comparable to, or modestly lower than, teriparatide, with comparable major adverse cardiovascular events — but this is observational, propensity-matched data, not a definitive head-to-head (Cosman 2022). The honest summary is that abaloparatide and teriparatide differ on receptor pharmacology, and possibly on some clinical endpoints, but the randomised evidence does not separate them decisively.

04. Palopegteriparatide — the same fragment engineered for continuity

Palopegteriparatide is a prodrug of PTH(1-34). The peptide is attached to a polyethylene-glycol carrier through a linker that is cleaved gradually in the body, releasing active teriparatide to produce sustained rather than pulsatile PTH exposure. Its purpose is different again: it is a PTH replacement therapy for adults with chronic hypoparathyroidism, the rare condition in which the parathyroid glands fail to produce enough PTH (EMA EPAR Yorvipath; Ascendis 2024).

The MHRA granted marketing authorisation in Great Britain in April 2024 and awarded it orphan drug status; the European Medicines Agency authorised it for the European Union (Ascendis 2024; EMA EPAR Yorvipath). In the pivotal programme, most patients reached serum calcium within the normal range and were able to step down from therapeutic doses of calcium supplements and active vitamin D (EMA EPAR Yorvipath).

This is the inversion that makes the class a useful case study in peptide engineering: for osteoporosis the pharmacology wants a transient pulse, while for replacement therapy it wants a steady plateau. The same fragment and the same receptor, engineered to opposite pharmacokinetic objectives — a point developed further in our explainer on peptide half-life engineering.

05. Reading the class like an evidence-graded reference

Peptide Data's four-tier evidence grading exists chiefly to discipline claims about compounds that have no licensing pathway — the grey-market research peptides whose human data are thin or absent. The PTH analogues here sit outside that treadmill: all three are licensed prescription medicines with regulatory assessment, and two carry NICE technology appraisals. The relevant discipline for a reader is different — distinguishing the licensed product, with its verified identity, purity and posology, from any grey-market "PTH fragment" sold as a research reagent, which is not the same article and carries no comparable assurance.

06. The UK regulatory frame, and the research-use-only boundary

Teriparatide and abaloparatide are prescription-only medicines (POM) under the Human Medicines Regulations 2012, which operate within the framework of the Medicines Act 1968; palopegteriparatide is likewise a POM holding an MHRA marketing authorisation (HMR 2012 / Medicines Act 1968; Ascendis 2024). NHS use is governed by NICE appraisal, not by a compound's mere availability. Legitimate clinical research with these agents in the UK proceeds through the clinical-trials framework for investigational medicinal products (CTIMPs), administered by the MHRA and the Health Research Authority.

None of this is consumption, dosing or self-administration advice, and nothing here implies that any peptide treats, cures or prevents any condition. PTH analogues are licensed medicines to be prescribed and supervised by clinicians. Research-grade peptides sold online for laboratory use are not those medicines, are not for human use, and should be treated as reference materials only.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.